Role of maternal plasma levels of placental growth factor for the prediction of maternal complications in preeclampsia according to the gestational age at onset

Prenatal Diagnosis

Volumn 34, Issue 7, 2014, Pages 706-710

  Meler, Eva ^a,b   Scazzocchio, Elena ^a,b   Peguero, Anna ^a   Triunfo, Stefania ^a   Gratacos, Eduard ^a   Figueras, Francesc ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PLACENTAL GROWTH FACTOR; BIOLOGICAL MARKER; PLACENTA PROTEIN;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FALSE POSITIVE RESULT; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; KIDNEY FAILURE; LUNG EDEMA; MAJOR CLINICAL STUDY; MATERNAL PLASMA; ONSET AGE; PLACENTAL GROWTH FACTOR PLASMA LEVEL; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SOLUTIO PLACENTAE; BLOOD; NEWBORN; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY PROTEINS; PROGNOSIS; YOUNG ADULT;

EID: 84924346299     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4390     Document Type: Article

References (39)

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7.
2. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008;21:521-6.
3. Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013;61(5):932-42.
4. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996;175:1365-70.
5. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376(9741):631-44.
6. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013;209(6):544.e1-544.e12.
7. Kozic JR, Benton SJ, Hutcheon JA, et al. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can 2011;33(10):995-1004.
8. Laskin S, Payne B, Hutcheon JA, et al. The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can 2011;33(9):900-8.
9. Payne B, Magee LA, Cote AM, et al. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can 2011;33(6):588-97.
10. Yen TW, Payne B, Qu Z, et al. Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can 2011;33(8):803-9.
11. Boucoiran I, Thissier-Levy S, Wu Y, et al. Risks for preeclampsia and small for gestational age: predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin A in singleton and multiple-gestation pregnancies. Am J Perinatol 2013;30(7):607-12.
12. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
13. Ohkuchi A, Hirashima C, Matsubara S, et al. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007;30:151-9.
14. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009;30(Suppl A):S38-42.
15. Chappell LC, Duckworth S, Griffin M. Plasma placental growth factor (PLGF) measurement in women presenting with suspected pre-eclampsia: the pelican study. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 2012;2(3):233-4.
16. Robinson HP, Fleming JE. A critical evaluation of sonar "crown-rump length" measurements. Br J Obstet Gynaecol 1975;82:702-10.
17. Figueras F, Meler E, Iraola A, et al. Customized birthweight standards for a Spanish population. Eur J Obstet Gynecol Reprod Biol 2008;136:20-4.
18. Saffer C. Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 2013;3(2):124-32.
19. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009;200:481.e1-7.
20. Sibiude J, Guibourdenche J, Dionne MD, et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012;7(11):e50208.
21. Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2013;83(1):177-81.
22. Qazi U, Lam C, Karumanchi SA, Petri M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 2008;35:631-4.
23. Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012;59(3):740-6.
24. Young B, Levine RJ, Salahuddin S, et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010;23(5):366-70.
25. Wikstrom AK, Larsson A, Eriksson UJ, et al. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007;109:1368-74.
26. Leanos-Miranda A, Campos-Galicia I, Ramirez-Valenzuela KL, et al. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia. Hypertension 2013;61(5):1118-25.
27. Molvarec A, Gullai N, Stenczer B, et al. Comparison of placental growth factor and fetal flow Doppler ultrasonography to identify fetal adverse outcomes in women with hypertensive disorders of pregnancy: an observational study. BMC Pregnancy Childbirth 2013;13:161.
28. Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24(10):1187-207.
29. Crispi F, Dominguez C, Llurba E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 2006;195:201-7.
30. Meler E, Figueras F, Mula R, et al. Prognostic role of uterine artery Doppler in patients with preeclampsia. Fetal Diagn Ther 2010;27(1):8-13.
31. Ghi T, Youssef A, Piva M, et al. The prognostic role of uterine artery Doppler studies in patients with late-onset preeclampsia. Am J Obstet Gynecol 2009;201:36.e1-5.
32. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196:326.e1-13.
33. Redman C. Point-of-care assay of placental growth factor to diagnose preeclampsia. Advances in Perinatol Medicine. ECPM Proceedings, Granada, Spain, 2010.
34. Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011;205(5):469.e1-8.
35. Myers J, Kenny L, McCowan L. Comparison of two placental growth factor immunoassays as an aid in the diagnosis of preterm preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 2011;1(3-4):201-1.
36. Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010;122(5):478-87.
37. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125(7):911-9.
38. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541-7.
39. Rana S, Schnettler WT, Powe C, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013;32:189-201.